JAK Inhibitors and Endothelial Dysfunction Under Inflammatory Stress

Study Background and Research Question

Patients with rheumatoid arthritis (RA) are at elevated risk for cardiovascular (CV) disease, largely due to chronic systemic inflammation. Key mediators of this risk are the proinflammatory cytokines tumor necrosis factor (TNF) and interleukin-17A (IL-17A), which together provoke endothelial cell (EC) dysfunction—a critical step in the pathogenesis of thrombosis. Endothelial dysfunction is marked by enhanced expression of adhesion molecules, increased procoagulant factors, and apoptosis. These processes promote leukocyte recruitment and disturb vascular homeostasis, underscoring the clinical importance of understanding how anti-inflammatory therapies, especially Janus kinase inhibitors (JAKi), influence vascular biology in inflammatory settings.

JAK inhibitors, including tofacitinib citrate (CP-690550 citrate), have transformed the management of autoimmune and inflammatory disorders by modulating the JAK-STAT signaling pathway, a key route for cytokine-driven immune responses. However, recent safety alerts regarding the risk of cardiovascular events in patients treated with JAKi have prompted new research into their direct vascular effects. The central research question addressed by Zavoriti and Miossec (ACR Open Rheumatology, 2025) is: How do various approved JAK inhibitors affect endothelial cell activation, inflammation, and thrombogenicity when ECs are challenged by TNF and IL-17A in vitro?

Key Innovation from the Reference Study

The distinguishing innovation of this study lies in its systematic, side-by-side analysis of six clinically relevant JAK inhibitors—tofacitinib, baricitinib, upadacitinib, peficitinib, ruxolitinib, and fedratinib—at two concentrations (1 μM and 10 μM) on human vascular ECs under severe proinflammatory stimulation. By examining effects on cytokine production, adhesion molecule expression, coagulation pathway factors, and apoptosis, the research delivers a multidimensional view of how JAKi class and dose shape endothelial responses. This comparative approach helps clarify both the anti-inflammatory benefits and potential prothrombotic liabilities that may contribute to observed cardiovascular risks in clinical populations.

Methods and Experimental Design Insights

The investigators used primary human vascular endothelial cells, exposing them to a combination of TNF and IL-17A to simulate the potent inflammatory milieu characteristic of RA and related disorders. Cells were treated with each JAK inhibitor at 1 μM and 10 μM, concentrations relevant to pharmacological research and, in some cases, plasma levels achieved in clinical use. The endpoints assessed included:

• Measurement of IL-6 and IL-8 cytokine secretion by ELISA
• Quantification of adhesion molecules (VCAM-1, ICAM-1, E-selectin) and coagulation/fibrinolysis gene expression by qRT-PCR
• Assessment of apoptosis via Annexin V staining

This design enabled direct comparison of dose-dependent and compound-specific effects on key determinants of vascular inflammation and hemostasis.

Core Findings and Why They Matter

Anti-inflammatory effects: All six JAK inhibitors, including tofacitinib citrate, reduced IL-6 secretion in ECs exposed to TNF+IL-17A. This demonstrates a consistent capacity for JAKi to dampen certain inflammatory signals, supporting their established role in immune regulation research.

Chemokine and adhesion molecule modulation: Only baricitinib and fedratinib reduced IL-8 overproduction at both concentrations. Fedratinib uniquely decreased VCAM-1 and E-selectin upregulation, while tofacitinib selectively reduced ICAM-1 and E-selectin induction at 1 μM. However, at 10 μM, most JAKi (including tofacitinib) paradoxically enhanced VCAM-1 and ICAM-1 expression in the presence of TNF+IL-17A. This concentration-dependent reversal could have implications for pro-adhesive and potentially prothrombotic effects at higher drug exposures.

Coagulation pathway impact: Peficitinib and fedratinib suppressed tissue factor upregulation at both concentrations, suggesting a protective effect against inflammation-induced procoagulant states. Ruxolitinib was effective only at 1 μM. Importantly, none of the JAKi prevented the downregulation of thrombomodulin, a key anticoagulant molecule, indicating a persistent prothrombotic risk despite anti-inflammatory actions.

Apoptosis and cytotoxicity: Both fedratinib and peficitinib were proapoptotic and cytotoxic for endothelial cells, raising concerns about their safety profile in contexts where endothelial preservation is desirable.

Collectively, these results suggest that while JAK inhibitors exhibit anti-inflammatory properties on endothelial cells, their capacity to mitigate prothrombotic changes and preserve anticoagulant function is limited. Some compounds, notably at higher concentrations, may even exacerbate certain risk factors for vascular events. These nuanced findings are highly relevant for researchers modeling inflammatory disorder mechanisms and for translational teams evaluating cardiovascular safety in drug development.

Comparison with Existing Internal Articles

Several internal resources have previously examined tofacitinib citrate (CP-690550 citrate) within the context of immune regulation and JAK-STAT signaling. For example, the article "Tofacitinib Citrate (CP-690550): Precision Modulation of JAK3 in Immune Research" details the selective inhibition of JAK3 and the downstream modulation of Th cell differentiation and cytokine profiles. The current reference study complements these insights by focusing on endothelial rather than lymphoid cells, highlighting that while tofacitinib is effective at suppressing certain inflammatory mediators, its impact on adhesion molecules and procoagulant factors is complex and dose-dependent.

The study also extends the comparative analysis presented in "JAK Inhibitors and Endothelial Dysfunction: Comparative Vascular Effects", which discusses the duality of JAKi in modulating both inflammation and thrombosis. Together, these resources underscore the importance of context-specific experimental design in immune regulation research and caution against generalizing anti-inflammatory efficacy to cardiovascular protection.

Limitations and Transferability

While the study offers valuable mechanistic insights, several limitations should be considered:

• In vitro model constraints: The use of isolated human endothelial cells and supraphysiological cytokine concentrations may not fully recapitulate the complexity of in vivo vascular inflammation or drug pharmacokinetics.
• JAK-STAT pathway specificity: TNF and IL-17A do not directly signal via JAK-STAT, so observed effects of JAKi may be mediated through indirect crosstalk with other cytokine networks or cell types.
• Concentration-dependent effects: The pro-adhesive effects seen at higher inhibitor concentrations highlight the need for careful dose selection in experimental and clinical contexts.

Therefore, while the findings are immediately relevant for inflammatory disorder research and endothelial assay systems, caution is warranted when extrapolating to whole-animal or clinical scenarios.

Protocol Parameters

• Endothelial cell treatment: Pre-treat human vascular ECs with tofacitinib citrate (or other JAKi) at 1 μM or 10 μM for 30 minutes prior to cytokine stimulation.
• Inflammatory stimulation: Add TNF and IL-17A to model synergistic inflammatory stress typical of RA-associated endothelial dysfunction.
• Outcome measurements: After 24 hours, assess IL-6 and IL-8 release by ELISA; quantify VCAM-1, ICAM-1, E-selectin, tissue factor, and thrombomodulin expression by qRT-PCR; evaluate apoptosis using Annexin V staining.
• Workflow note: For JAK-STAT pathway specificity studies in immune or vascular models, consider experimental concentrations of tofacitinib citrate in the range of 10 nM to 1 μM as reported in product documentation, but validate for each assay system.

Research Support Resources

For researchers aiming to dissect JAK-STAT signaling and model endothelial or immune responses under inflammatory conditions, Tofacitinib citrate (CP-690550 citrate) (SKU A4135) is a well-characterized, selective JAK3 inhibitor available from APExBIO. Its established use in immune regulation and inflammatory disorder research, along with detailed product documentation and solubility profiles, make it suitable for both cell-based and mechanistic studies. For protocol optimization, consult recent comparative studies and validated internal workflows for guidance on concentration selection and assay endpoints.